Celularity Inc (CELU) - Net Assets
Based on the latest financial reports, Celularity Inc (CELU) has net assets worth $-20.09 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($114.24 Million) and total liabilities ($134.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CELU asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-20.09 Million |
| % of Total Assets | -17.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | -52.78% |
| 10-Year Change | N/A |
| Growth Volatility | 199.73 |
Celularity Inc - Net Assets Trend (2018–2024)
This chart illustrates how Celularity Inc's net assets have evolved over time, based on quarterly financial data. Also explore CELU current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Celularity Inc (2018–2024)
The table below shows the annual net assets of Celularity Inc from 2018 to 2024. For live valuation and market cap data, see CELU market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.84 Million | -78.43% |
| 2023-12-31 | $40.96 Million | -79.41% |
| 2022-12-31 | $198.90 Million | +100.07% |
| 2021-12-31 | $99.42 Million | +431.28% |
| 2020-12-31 | $18.71 Million | -86.43% |
| 2019-12-31 | $137.86 Million | +109646.44% |
| 2018-12-31 | $-125.85K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celularity Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 89968190200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.02% |
| Other Comprehensive Income | $-5.00K | -0.06% |
| Other Components | $908.52 Million | 10280.90% |
| Total Equity | $8.84 Million | 100.00% |
Celularity Inc Competitors by Market Cap
The table below lists competitors of Celularity Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunyvers SA
PA:ALHUN
|
$27.60 Million |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
$27.61 Million |
|
YoungWoo DSP Co.Ltd
KQ:143540
|
$27.62 Million |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
$27.62 Million |
|
Q-Gold Resources Ltd
V:QGR
|
$27.60 Million |
|
Silla Textile Co.Ltd
KQ:001000
|
$27.59 Million |
|
Petratherm Ltd
AU:PTR
|
$27.59 Million |
|
Fortune Bay Corp
V:FOR
|
$27.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celularity Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,960,000 to 8,837,000, a change of -32,123,000 (-78.4%).
- Net loss of 57,892,000 reduced equity.
- New share issuances of 6,000,000 increased equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 19,774,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.89 Million | -655.11% |
| Share Issuances | $6.00 Million | +67.9% |
| Other Comprehensive Income | $-5.00K | -0.06% |
| Other Changes | $19.77 Million | +223.76% |
| Total Change | $- | -78.43% |
Book Value vs Market Value Analysis
This analysis compares Celularity Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.04 | $0.96 | x |
| 2019-12-31 | $57.75 | $0.96 | x |
| 2020-12-31 | $10.16 | $0.96 | x |
| 2021-12-31 | $14.83 | $0.96 | x |
| 2022-12-31 | $13.28 | $0.96 | x |
| 2023-12-31 | $2.11 | $0.96 | x |
| 2024-12-31 | $0.40 | $0.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celularity Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -655.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -106.77%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 15.01x
- Recent ROE (-655.11%) is below the historical average (-356.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -0.01% | 710.49x | 0.00x | $11.49K |
| 2019 | -153.69% | -1001.94% | 0.04x | 3.78x | $-225.67 Million |
| 2020 | -1112.77% | -1458.42% | 0.03x | 23.03x | $-210.10 Million |
| 2021 | -100.70% | -469.27% | 0.05x | 4.17x | $-110.06 Million |
| 2022 | 7.14% | 78.95% | 0.04x | 2.02x | $-5.70 Million |
| 2023 | -479.24% | -862.04% | 0.16x | 3.51x | $-200.39 Million |
| 2024 | -655.11% | -106.77% | 0.41x | 15.01x | $-58.78 Million |
Industry Comparison
This section compares Celularity Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celularity Inc (CELU) | $-20.09 Million | 0.00% | N/A | $27.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more